Despite significant cumulative losses, the firm maintains a robust liquidity position with a current ratio of 9.54 as of 2026Q1, though this is heavily influenced by $33.1M in deferred revenue obligations.
| Total Current Assets | 677.55M | 393.19M | 377.44M | 236.21M | 275.89M | 348.67M | 43.59M | 9.76M |
| Cash & Short-Term Investments | 666.22M | 377.1M | 372.15M | 232.41M | 262.83M | 346.07M | 41.7M | 6M |
| Cash Only | 159.86M | 129.88M | 224.25M | 128.1M | 54.91M | 346.07M | 41.7M | 6M |
| Short-Term Investments | 506.36M | 247.22M | 147.9M | 104.31M | 207.91M | 0 | 0 | 0 |
| Accounts Receivable | 4.61M | 4.6M | 173K | 505K | 7.66M | 0 | 0 | 0 |
| Days Sales Outstanding | 35.15 | 13.58 | 0.83 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 6.72M | 11.48M | 5.12M | 3.29M | 5.4M | 0 | 100K | 3.25M |
| Total Non-Current Assets | 58.88M | 55.47M | 61.29M | 67.54M | 66.5M | 17.66M | 5.79M | 1.33M |
| Property, Plant & Equipment | 53.1M | 50.37M | 56.31M | 62.61M | 61.91M | 12.32M | 4.62M | 1.33M |
| Fixed Asset Turnover | 0.81x | 2.46x | 1.34x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 4.95M | 0 | 0 | 0 | 0 | 5.34M | 1.16M | 0 |
| Other Non-Current Assets | 5.78M | 5.1M | 4.98M | 4.93M | 4.6M | 0 | 0 | 0 |
| Total Assets | 736.43M | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M | 49.38M | 11.09M |
| Asset Turnover | 0.09x | 0.28x | 0.17x | - | - | - | - | - |
| Asset Growth % | 139.99% | 2.26% | 44.44% | -11.28% | -6.54% | 641.89% | 345.09% | - |
| Total Current Liabilities | 71.04M | 64.21M | 156.95M | 46.59M | 25.57M | 16.64M | 29.27M | 4.29M |
| Accounts Payable | 7.9M | 3.55M | 17.21M | 11.15M | 7.86M | 6.56M | 7.07M | 3.19M |
| Days Payables Outstanding | 1.42K | 155.07 | 773.73 | 654.21 | - | - | 4.8K | 16.2K |
| Short-Term Debt | 4.48M | 4.4M | 0 | 0 | 0 | 0 | 0 | 750K |
| Deferred Revenue (Current) | 105.83M | 29.57M | 117.23M | 17.68M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.59M | 26.69M | 11.57M | 9.26M | 10.64M | 840K | 21.08M | 0 |
| Current Ratio | 9.54x | 6.12x | 2.40x | 5.07x | 10.79x | 20.96x | 1.49x | 2.27x |
| Quick Ratio | 9.54x | 6.12x | 2.40x | 5.07x | 10.79x | 20.96x | 1.49x | 2.27x |
| Cash Conversion Cycle | -1.38K | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 143.48M | 151.39M | 58.85M | 77.91M | 45.41M | 2.18M | 68.83M | 18.95M |
| Long-Term Debt | 34.58M | 34.79M | 0 | 0 | 0 | 0 | 67.76M | 0 |
| Capital Lease Obligations | 37.04M | 0 | 39M | 42.88M | 43.87M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 108.89M | 5.26M | 3.7M | 2.71M | 1.53M | 2.18M | 0 | 18.95M |
| Total Liabilities | 214.51M | 215.6M | 215.8M | 124.5M | 70.98M | 18.81M | 98.11M | 23.24M |
| Total Debt | 39.06M | 39.19M | 42.72M | 46.04M | 47M | 0 | 67.76M | 750K |
| Net Debt | -120.8M | -90.69M | -181.54M | -82.06M | -7.91M | -346.07M | 26.07M | -5.25M |
| Debt / Equity | 0.07x | 0.17x | 0.19x | 0.26x | 0.17x | - | - | - |
| Debt / EBITDA | -0.28x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.86x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -29.86x | - | - | -7739.00x |
| Total Equity | 521.92M | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M | -48.73M | -12.15M |
| Equity Growth % | 133.19% | 4.54% | 24.37% | -33.96% | -21.9% | 813.17% | -301.12% | - |
| Book Value per Share | 7.96 | 2.81 | 3.02 | 3.49 | 5.75 | 7.47 | -1.11 | -0.28 |
| Total Shareholders' Equity | 521.92M | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M | -48.73M | -12.15M |
| Common Stock | 8K | 7K | 6K | 5K | 5K | 5K | 1K | 50K |
| Retained Earnings | -521.72M | -477.21M | -438.59M | -365.89M | -230.54M | -122.03M | -48.08M | -12.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.75M | -3.83M | -3.36M | -2.72M | -1.75M | -2.02M | -1.06M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical milestone funding dependency
According to the most recent balance sheet data, GLUE maintains a current ratio of 9.54 as of 2026Q1, yet this liquidity buffer is heavily contingent upon the timing of milestone-driven deferred revenue rather than consistent, self-sustaining cash inflows from core biotechnology operations.
While the high current ratio suggests a strong short-term cushion, investors should monitor the volatility of this metric, which has fluctuated significantly from 2.40 to 9.54 over the last six quarters. This instability implies that the company's liquidity is highly sensitive to the recognition of partnership-related revenue, leaving the firm vulnerable to cash crunches if clinical milestones are delayed.
Based on reported financial statements, GLUE maintains a conservative capital structure with a debt-to-equity ratio of 0.07 as of 2026Q1, indicating that the firm has avoided significant reliance on traditional debt financing to fund its extensive research and development pipeline.
The low leverage profile appears strategic, allowing the company to avoid interest expense burdens while it remains in a pre-commercial, cash-burning phase. However, the lack of debt also suggests that the company must rely almost exclusively on equity dilution or partnership capital to sustain its operations, which warrants further investigation into the long-term cost of capital.
As evidenced by the company's balance sheet, retained earnings have deteriorated to -$521.7M by 2026Q1, reflecting the cumulative impact of sustained operating losses inherent in the development of the QuEEN platform and associated clinical trial programs.
The consistent decline in retained earnings highlights the significant capital intensity required to advance molecular glue degraders through the clinical pipeline. Investors should monitor whether future milestone payments can eventually offset this erosion, as the current trajectory suggests that equity value is being consumed to fund ongoing scientific discovery.
Based on the 2026Q1 balance sheet, the presence of $33.1M in deferred revenue serves as a critical accounting distortion, as this liability represents future performance obligations rather than a traditional debt burden that would require immediate cash repayment.
This deferred revenue balance effectively masks the true operational cash position, as it represents cash already received that has not yet been recognized as income. Analysts should be cautious in interpreting the current ratio, as the eventual recognition of this revenue will not provide additional cash inflows, potentially overstating the company's actual financial flexibility.
Quick answers to the most common questions about buying GLUE stock.
As of 2025, Monte Rosa Therapeutics, Inc. (GLUE) had total assets of $448.7M including $393.2M in current assets.
Monte Rosa Therapeutics, Inc. (GLUE) carries total debt of $39.2M, offset by $377.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Monte Rosa Therapeutics, Inc. (GLUE) has total shareholders' equity (book value) of $233.1M ($2.81 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Monte Rosa Therapeutics, Inc. (GLUE) reported a current ratio of 6.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.